The New Possibilities in Early Diagnosis of Preeclampsia by Soluble fms-Like Tyrosine Kinase-1 and Placental Growth Factor in 16-20 Weeks Gestation

BEŇOVSKÁ, Miroslava, Aneta OPLUŠTILOVÁ, Jana PINKAVOVÁ, Zuzana HODICKÁ a Zdeňka ČERMÁKOVÁ. The New Possibilities in Early Diagnosis of Preeclampsia by Soluble fms-Like Tyrosine Kinase-1 and Placental Growth Factor in 16-20 Weeks Gestation. LABORATORY MEDICINE. OXFORD: OXFORD UNIV PRESS, 2018, roč. 49, č. 2, s. 112-117. ISSN 0007-5027. Dostupné z: https://dx.doi.org/10.1093/labmed/lmx076.

Základní údaje

• Originální název: The New Possibilities in Early Diagnosis of Preeclampsia by Soluble fms-Like Tyrosine Kinase-1 and Placental Growth Factor in 16-20 Weeks Gestation
• Autoři: BEŇOVSKÁ, Miroslava (203 Česká republika, garant, domácí), Aneta OPLUŠTILOVÁ (203 Česká republika), Jana PINKAVOVÁ (203 Česká republika), Zuzana HODICKÁ (203 Česká republika, domácí) a Zdeňka ČERMÁKOVÁ (203 Česká republika, domácí).
• Vydání: LABORATORY MEDICINE, OXFORD, OXFORD UNIV PRESS, 2018, 0007-5027.

Další údaje

• Originální jazyk: angličtina
• Typ výsledku: Článek v odborném periodiku
• Obor: 20602 Medical laboratory technology
• Stát vydavatele: Velká Británie a Severní Irsko
• Utajení: není předmětem státního či obchodního tajemství
• Impakt faktor: Impact factor: 1.020
• Kód RIV: RIV/00216224:14110/18:00104136
• Organizační jednotka: Lékařská fakulta
• Doi: http://dx.doi.org/10.1093/labmed/lmx076
• UT WoS: 000435092600006
• Klíčová slova anglicky: preeclampsia; angiogenic factors; placental growth factor; sFlt-1; PIGF; sFlt-1/PIGF ratio
• Štítky: 14110411, 14110616, rivok
• Příznaky: Mezinárodní význam, Recenzováno

Anotace

Background: Soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) ate used in diagnosing preeclampsia (PE), but their potential in early prediction in pregnant women at 16 to 20 weeks gestation (WG) has remained unexplored. Methods: We retrospectively measured serum levels of sFlt-1 and PIGF in 120 pregnant women at 16 to 20 WG. Among these women, 16 had early-onset PE and 23 had late-onset PE. Results: Compared with normal pregnancy values, in the serum of women in whom PE later developed, sFlt-1 values increased (P <.001), values of PIGF decreased (P = .001), and the sFlt-1/PIGF ratio increased (P <.001) as early as 16 to 20 WG. Receiver operating characteristic (ROC) curve analysis for the sFlt-1/PIGF ratio at 16 to 20 WG showed an area under the curve (AUC) value of 0.863 (95% confidence interval [CI], 0.788-0.918), P <.001, sensitivity of 74.4%, and specificity of 86.6 degrees k for PE in general; and AUC of 0.970 (95% CI, 0.913-0.994), P <.001, sensitivity of 100%, and specificity of 81.5% for early-onset PE only. Also, we determined the 5th and 95th percentiles for sFlt-1, PIGF, and sFlt-1/PIGF ratio values of healthy pregnant women. Conclusion: sFlt-1 and PIGF and, in particular, the sFlt-1/PIGF ratio can detect PE as early as 16 to 20 WG-as long as 10 to 15 weeks before PE onset.